At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab, Ociperlimab, and 5 other interventions for Non Small Cell Lung Cancer. Completed, enrolled 121 participants across 14 sites.
Detailed Summary
This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with non-small cell lung cancer (NSCLC) that is able to be removed by surgery.
Study Details
Timeline
Interventions
Administered as an intravenous infusion once every 3 weeks
Administered as an intravenous infusion once every 3 weeks
Administered as an intravenous infusion once every 3 weeks
75 mg/m\^2 administered as an intravenous infusion once every 3 weeks
Administered as an intravenous infusion once every 3 weeks at an area under the curve (AUC) of 5 mg/mL/min
500 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with non-squamous NSCLC
175 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with squamous NSCLC